AstraZeneca’s Strategic Move to Wall Street
AstraZeneca delists ADRs from Nasdaq for NYSE ordinary shares, attracting new U.S. investors.
AstraZeneca delists ADRs from Nasdaq for NYSE ordinary shares, attracting new U.S. investors.
FWD Group plans a $500 million IPO in Hong Kong next week, sources say.